Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	197.53	58.21	25.56	35.1	35.41
Short-Term Investments	154.77	182.81	210.66	167.82	182.75
Cash & Short-Term Investments	352.31	241.02	236.22	202.92	218.16
Cash Growth	46.17%	2.03%	16.41%	-6.99%	93.21%
Accounts Receivable	-	2.1	0.54	0.23	3.64
Other Current Assets	5.17	6.81	5.44	4.37	4.2
Total Current Assets	357.48	249.92	242.2	207.52	226
Net Property, Plant & Equipment	7.07	9.58	12.39	15.97	7.37
Other Long-Term Assets	1.74	1.21	3.1	3.2	1.63
Total Assets	366.28	260.72	257.69	226.69	235
Accounts Payable	1.59	1.16	2.76	3.64	4.79
Accrued Expenses	9.05	7.69	8.73	9.55	9.23
Current Portion of Leases	2.4	2.19	2.19	2.6	-
Unearned Revenue	-	-	-	0.93	4.71
Other Current Liabilities	-	-	-	-	0.47
Total Current Liabilities	13.05	11.04	13.68	16.73	19.2
Long-Term Leases	4.04	6.44	8.63	10.82	-
Other Long-Term Liabilities	0.2	0.2	0.2	0.2	4.26
Total Long-Term Liabilities	4.24	6.64	8.83	11.02	4.26
Total Liabilities	17.28	17.68	22.5	27.74	23.46
Common Stock	0.07	0.05	0.06	0.05	0.04
Additional Paid-in Capital	943.04	762.25	744.94	612.03	514.36
Accumulated Other Comprehensive Income	0.17	0.13	-0.14	-0.8	-0.4
Retained Earnings	-594.28	-519.4	-509.67	-412.34	-302.47
Shareholders' Equity	349	243.03	235.19	198.94	211.54
Total Liabilities & Equity	366.28	260.72	257.69	226.69	235
Total Debt	6.44	8.63	10.82	13.42	0
Net Cash (Debt)	345.86	232.39	225.4	189.5	218.16
Net Cash Growth	48.83%	3.10%	18.95%	-13.14%	93.21%
Net Cash Per Share	5.46	3.75	3.68	4.21	6.17
Book Value	349	243.03	235.19	198.94	211.54
Book Value Per Share	5.51	3.92	3.84	4.42	5.98
Tangible Book Value	349	243.03	235.19	198.94	211.54
Tangible Book Value Per Share	5.51	3.92	3.84	4.42	5.98

Updated Feb 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q